{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:34:24Z","timestamp":1788280464992,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01455-5","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T09:34:01Z","timestamp":1774863241000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Management of hematological toxicities after BCMA-directed CAR-T cell therapy"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5335-9533","authenticated-orcid":false,"given":"Joselle","family":"Cook","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5144-3467","authenticated-orcid":false,"given":"Supriya","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9195-1589","authenticated-orcid":false,"given":"Nadine","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8360-2952","authenticated-orcid":false,"given":"Matthew","family":"Rees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lay She","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0964-098X","authenticated-orcid":false,"given":"Radhika","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"De Menezes Silva Corraes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7345-8045","authenticated-orcid":false,"given":"Kristina","family":"Helms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahma","family":"Warsame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7477-3004","authenticated-orcid":false,"given":"David","family":"Dingli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6890-969X","authenticated-orcid":false,"given":"Wilson","family":"Gonsalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8573-9434","authenticated-orcid":false,"given":"Taxiarchis","family":"Kourelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3853-5196","authenticated-orcid":false,"given":"Morie","family":"Gertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Hayman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5651-1411","authenticated-orcid":false,"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4342-364X","authenticated-orcid":false,"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Hwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amie","family":"Fonder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1523-7388","authenticated-orcid":false,"given":"Leif","family":"Bergsagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udit","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Wiedmeier-Nutor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9117-8696","authenticated-orcid":false,"given":"Saurabh","family":"Chhabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8377-8111","authenticated-orcid":false,"given":"Sikander","family":"Ailawadhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9314-9933","authenticated-orcid":false,"given":"Ricardo","family":"Parrondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1556-6416","authenticated-orcid":false,"given":"Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"1455_CR1","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos M-V, et al. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. New England Journal of Medicine. 2023;389:335\u201347.","journal-title":"New England Journal of Medicine"},{"key":"1455_CR2","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. New England Journal of Medicine. 2023;388:1002\u201314.","journal-title":"New England Journal of Medicine"},{"key":"1455_CR3","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1182\/blood-2021-145155","volume":"138","author":"M Delforge","year":"2021","unstructured":"Delforge M, Shah N, Rodr\u00edguez-Otero P, Braverman J, Dhanda D, Shi L, et al. Updated Health-Related Quality of Life Results from the KarMMa Clinical Study in Patients with Relapsed and Refractory Multiple Myeloma Treated with the B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Idecabtagene Vicleucel (ide-cel, bb2121). Blood. 2021;138:2835.","journal-title":"Blood"},{"key":"1455_CR4","first-page":"2460","volume":"141","author":"T Jain","year":"2023","unstructured":"Jain T, Olson TS, Locke FL. How I treat cytopenias after CAR T-cell therapy. Blood. 2023;141:2460\u20139.","journal-title":"Blood"},{"key":"1455_CR5","doi-asserted-by":"publisher","first-page":"5479","DOI":"10.1182\/bloodadvances.2023012522","volume":"8","author":"ML Palacios-Berraquero","year":"2024","unstructured":"Palacios-Berraquero ML, Rodriguez-Marquez P, Calleja-Cervantes ME, Berastegui N, Zabaleta A, Burgos L, et al. Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in multiple myeloma. Blood Adv. 2024;8:5479\u201392.","journal-title":"Blood Adv"},{"key":"1455_CR6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jcyt.2024.08.007","volume":"27","author":"H Cheng","year":"2025","unstructured":"Cheng H, Shao L, Wang D, Chen Y, Sun Y, Chen Z, et al. Comprehensive characterization of cytopenia after chimeric antigen receptor-T cell infusion in patients with relapsed or refractory multiple myeloma. Cytotherapy. 2025;27:16\u201324.","journal-title":"Cytotherapy"},{"key":"1455_CR7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-023-01465-x","volume":"16","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Hansen DK, Bansal R, Sesques P, Ailawadhi S, Logue JM, et al. The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma. Journal of Hematology & Oncology. 2023;16:88.","journal-title":"Journal of Hematology & Oncology"},{"key":"1455_CR8","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jcyt.2023.01.011","volume":"25","author":"S Ma","year":"2023","unstructured":"Ma S, Li H, Zhou D, Zhang X, Shi M, Cao J, et al. Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma. Cytotherapy. 2023;25:653\u20138.","journal-title":"Cytotherapy"},{"key":"1455_CR9","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1038\/s41409-022-01659-w","volume":"57","author":"J Cook","year":"2022","unstructured":"Cook J, Gonsalves WI, Gertz MA, Visram A, Warsame R, Lacy MQ, et al. Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis. Bone Marrow Transplant. 2022;57:1007\u20139.","journal-title":"Bone Marrow Transplant"},{"key":"1455_CR10","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jtct.2023.05.012","volume":"29","author":"JA Davis","year":"2023","unstructured":"Davis JA, Sborov DW, Wesson W, Julian K, Abdallah AO, McGuirk JP, et al. Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy. Transplant Cell Ther. 2023;29:567\u201371.","journal-title":"Transplant Cell Ther"},{"key":"1455_CR11","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jtct.2023.08.004","volume":"29","author":"M Bhutani","year":"2023","unstructured":"Bhutani M. Boosting CAR T cytopenias with backup autologous stem cells. Transplantation and Cellular Therapy. 2023;29:535\u20136.","journal-title":"Transplantation and Cellular Therapy"},{"key":"1455_CR12","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1182\/blood-2024-210725","volume":"144","author":"K Yadav","year":"2024","unstructured":"Yadav K, Patel TH, Bachu R, Esselmann J, Rein LE, Szabo A, et al. Application of Stem Cell Boost for Immune Effector Cell Associated Hematotoxicity (ICAHT) Following BCMA Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Multiple Myeloma (MM). Blood. 2024;144:254.","journal-title":"Blood"},{"key":"1455_CR13","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s41409-024-02233-2","volume":"59","author":"M Mohan","year":"2024","unstructured":"Mohan M, Szabo A, Patwari A, Esselmann J, Patel T, Bachu R, et al. Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma. Bone Marrow Transplantation. 2024;59:647\u201352.","journal-title":"Bone Marrow Transplantation"},{"key":"1455_CR14","doi-asserted-by":"publisher","first-page":"5479","DOI":"10.1182\/bloodadvances.2023012522","volume":"8","author":"ML Palacios-Berraquero","year":"2024","unstructured":"Palacios-Berraquero ML, Rodriguez-Marquez P, Calleja-Cervantes ME, Berastegui N, Zabaleta A, Burgos L, et al. Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in multiple myeloma. Blood Advances. 2024;8:5479\u201392.","journal-title":"Blood Advances"},{"key":"1455_CR15","doi-asserted-by":"publisher","first-page":"E179","DOI":"10.1002\/ajh.26940","volume":"98","author":"JW Jacobs","year":"2023","unstructured":"Jacobs JW, Diaz M, Arevalo Salazar DE, Tang A, Stephens LD, Booth GS, et al. United States blood pricing: A cross-sectional analysis of charges and reimbursement at 200 US hospitals. American Journal of Hematology. 2023;98:E179\u2013E82.","journal-title":"American Journal of Hematology"},{"key":"1455_CR16","doi-asserted-by":"publisher","first-page":"238.e1","DOI":"10.1016\/j.jtct.2025.01.887","volume":"31","author":"D Waddell","year":"2025","unstructured":"Waddell D, Collins J, Sadrameli S. Utility of Thrombopoietin Receptor Agonists for Prolonged Thrombocytopenia After Chimeric Antigen Receptor T-cell Therapy. Transplantation and Cellular Therapy. 2025;31:238.e1\u2013.e12.","journal-title":"Transplantation and Cellular Therapy"},{"key":"1455_CR17","doi-asserted-by":"publisher","first-page":"253","DOI":"10.6004\/jadpro.2024.15.4.3","volume":"15","author":"CL Cao","year":"2024","unstructured":"Cao CL, Martinez A, Dains J. Growth Factor in the Setting of CAR T-Cell Therapy: To Use or Not to Use. J Adv Pract Oncol. 2024;15:253\u201364.","journal-title":"J Adv Pract Oncol"},{"key":"1455_CR18","doi-asserted-by":"publisher","first-page":"e374","DOI":"10.1016\/S1470-2045(24)00094-9","volume":"25","author":"Y Lin","year":"2024","unstructured":"Lin Y, Qiu L, Usmani S, Joo CW, Costa L, Derman B, et al. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee. The Lancet Oncology. 2024;25:e374\u2013e87.","journal-title":"The Lancet Oncology"},{"key":"1455_CR19","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1038\/s41409-021-01223-y","volume":"56","author":"N Ahmed","year":"2021","unstructured":"Ahmed N, Li L, Rojas P, Covut F, Reese-Koc J, Kolk M, et al. Significant costs and low utilization of stored peripheral blood stem cells for salvage autologous transplant in multiple myeloma patients including those meeting mSMART criteria. Bone Marrow Transplant. 2021;56:1458\u201361.","journal-title":"Bone Marrow Transplant"},{"key":"1455_CR20","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/j.bbmt.2020.04.030","volume":"26","author":"F Krummradt","year":"2020","unstructured":"Krummradt F, Sauer S, Pavel P, Klein EM, Schmitt A, Kriegsmann M, et al. Storage, Utilization, and Disposal of Hematopoietic Stem Cell Products in Patients with Multiple Myeloma. Biol Blood Marrow Transplant. 2020;26:1589\u201396.","journal-title":"Biol Blood Marrow Transplant."},{"key":"1455_CR21","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1016\/j.bbmt.2020.07.019","volume":"26","author":"S Chhabra","year":"2020","unstructured":"Chhabra S, Thapa B, Szabo A, Konings S, D\u2019Souza A, Dhakal B, et al. Utilization and Cost Implications of Hematopoietic Progenitor Cells Stored for a Future Salvage Autologous Transplantation or Stem Cell Boost in Myeloma Patients. Biol Blood Marrow Transplant. 2020;26:2011\u20137.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1455_CR22","doi-asserted-by":"publisher","first-page":"5641","DOI":"10.1182\/bloodadvances.2025016689","volume":"9","author":"JW de Boer","year":"2025","unstructured":"de Boer JW, Keijzer K, van Dorp S, Mutsaers PGNJ, Niezink AGH, van Doesum JA, et al. Population-based validation of the CAR-HEMATOTOX for hematotoxicity, infections, and survival after CART in R\/R LBCL. Blood Advances. 2025;9:5641\u201350.","journal-title":"Blood Advances"},{"key":"1455_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1019548","volume":"13","author":"H Li","year":"2022","unstructured":"Li H, Zhao L, Sun Z, Yao Y, Li L, Wang J, et al. Prolonged hematological toxicity in patients receiving BCMA\/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma. Front Immunol. 2022;13:1019548.","journal-title":"Front Immunol"},{"key":"1455_CR24","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1182\/bloodadvances.2024014255","volume":"9","author":"ZM Avigan","year":"2025","unstructured":"Avigan ZM, Bodnar S, Pan D, Catlett J, Richter J, Sanchez LJ, et al. Delayed neutrophil recovery following BCMA CAR-T therapy in Duffy-null myeloma does not impact severe infections or survival. Blood Adv. 2025;9:202\u20136.","journal-title":"Blood Adv"},{"key":"1455_CR25","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1182\/blood.2023020578","volume":"142","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Subklewe M, Aljurf M, Bachy E, Balduzzi A, Barba P, et al. Immune effector cell\u2013associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations. Blood. 2023;142:865\u201377.","journal-title":"Blood"},{"key":"1455_CR26","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1182\/bloodadvances.2021004554","volume":"5","author":"PG Miller","year":"2021","unstructured":"Miller PG, Sperling AS, Brea EJ, Leick MB, Fell GG, Jan M, et al. Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. Blood Adv. 2021;5:2982\u20136.","journal-title":"Blood Adv"},{"key":"1455_CR27","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1182\/bloodadvances.2021005747","volume":"6","author":"R Teipel","year":"2022","unstructured":"Teipel R, Kroschinsky F, Kramer M, Kretschmann T, Egger-Heidrich K, Kr\u00fcger T, et al. Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment. Blood Advances. 2022;6:1941\u20136.","journal-title":"Blood Advances"},{"key":"1455_CR28","doi-asserted-by":"publisher","first-page":"927.e1","DOI":"10.1016\/j.jtct.2024.06.008","volume":"30","author":"SR Goldsmith","year":"2024","unstructured":"Goldsmith SR, Shouse G, Wong FL, Bosworth A, Iukuridze A, Chen S, et al. Clonal Hematopoiesis is Associated With Severe Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T-Cell (CART) Therapy. Transplant Cell Ther. 2024;30:927.e1\u2013.e9.","journal-title":"Transplant Cell Ther"},{"key":"1455_CR29","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1182\/bloodadvances.2021005747","volume":"6","author":"R Teipel","year":"2022","unstructured":"Teipel R, Kroschinsky F, Kramer M, Kretschmann T, Egger-Heidrich K, Kr\u00fcger T, et al. Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment. Blood Adv. 2022;6:1941\u20136.","journal-title":"Blood Adv"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01455-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01455-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01455-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T19:16:22Z","timestamp":1774984582000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01455-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1455"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01455-5","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]},"assertion":[{"value":"16 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RP: advisory board role for Sanofi Aventis and Astra Zeneca, research funding from Bristol Myers Squibb Foundation and GlaxoSmithKline; SC: honoraria from Sanofi, Ascentage Pharma, Sobi, Legend Biotech, Pfizer, BMS and research funding from Johnson & Johnson, Takeda, C4 Therapeutics, Cynata Therapeutics, Cullinan Therapeutics, Abbvie, Ascentage Pharma, AstraZeneca; MG: personal fees from Ionis\/Akcea, honorarium from Alnylym, personal fees from Prothena, personal fees from Sanofi, personal fees from Janssen, personal fees for Data Safety Monitoring board from Abbvie & Arcellex, fees from Johnson & Johnson, Honoraria for Astra Zeneca, Medscape, Dava Oncology. Alexion; PK: Honoraria: Pharmacyclics, Sanofi, BeiGene, MustangBio, AstraZeneca, AbbVie. Consulting or Advisory Role: Sanofi. Research Funding: Amgen, Takeda, Sanofi, AbbVie, GlaxoSmithKline, Sorrento Therapeutics, Karyopharm Therapeutics, Regeneron, Ichnos Sciences, Bristol Myers Squibb\/Celgene; PLB: Consultant: Oncopeptidfes. Salarius, Radmetrix, Omeros, CellCentric, AbbVie, Pfizer; SK: Consulting or Advisory Role: Takeda, Janssen Oncology, Genentech\/Rocher, Abbvie, BMS\/Celgene, Pfizer, Regeneron, Sanofi, K36 Therapeutics; travel, accomodation and expenses: Abbvie, pfizer; Research funding: Takeda, Abbvie, Novartis, Sanofi, Janssen Oncology, MedImmune, Roche\/Genentech, CARsgen Therapeutics, Allogene Therapeutics, GSK, Regeneron, BMS\/Celgene; SA: Consulting or Advisory Role: Takeda, BeiGene, GlaxoSmithKline, Sanofi, Pharmacyclics, BMS, Amgen, Janssen, Regeneron, Cellectar. Research Funding: Pharmacyclics, Janssen Biotech, Cellectar, BMS, Amgen, GlaxoSmithKline, AbbVie, Ascentage Pharma, Sanofi; RF: consultancy for AbbVie, Adaptive, Amgen, Apple, BMS\/Celgene, GSK, Janssen, Karyopharm, Pfizer, RA Capital, Regeneron, Sanofi. Scientific advisory board: Caris Life Sciences. Board of directors: Antengene. Patent for FISH in multiple myeloma; YL: advisory board role for Janssen, Sanofi, BMS, Regeneron, Genentech, Tesserae, Legend, NexT Therapeutics, steering committee for Janssen, Kite\/Gilead, research funding from Janssen, BMS, scientific advisory board for Nonimmune, Caribou and sata safety monitor board for Pfizer. Others: No conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"49"}}